Scholarlink

Background <p>Gastric cancer (GC) remains a leading cause of cancer-related mortality, and current diagnostic biomarkers lack sufficient sensitivity and specificity. tRNA-derived fragments (tRFs), an emerging class of non-coding RNAs, have garnered attention for their stability and regulatory roles in carcinogenesis.</p> Main body <p>This review adopts a comparative perspective to evaluate the distinctive roles of tRFs in GC relative to other non-coding RNAs, particularly microRNAs (miRNAs). We summarize tRF biogenesis and classification, highlighting their unique mechanistic repertoire that encompasses both AGO2-dependent gene silencing and non-canonical protein interactions. Dysregulated tRF profiles in patient samples reveal promising diagnostic candidates (e.g., tRF-23-Q99P9P9NDD, tRF-17-18VBY9M) that demonstrate superior performance to conventional markers. However, we critically examine translational barriers including functional heterogeneity, detection challenges, and the absence of registered clinical trials. We also dissect sources of contradictory findings and propose standardized frameworks for future investigation.</p> Conclusions <p>tRFs represent functionally versatile regulators with distinct advantages over miRNAs in diagnostic applications. Their clinical translation requires overcoming methodological standardization gaps and evidence thresholds through interdisciplinary efforts integrating multi-omics profiling, advanced delivery systems, and rigorous clinical validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

tRF and gastric cancer: molecular mechanism exploration and novel strategies for precision diagnosis and therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月16日

查看全文
  • Hongping Jia,
  • Yiyao Duan,
  • Yun Huang,
  • Jun Hu,
  • Xirui Fan,
  • Rui Gong,
  • Ningyan Zhang,
  • Rong Qin,
  • Hui Wang

摘要

Background

Gastric cancer (GC) remains a leading cause of cancer-related mortality, and current diagnostic biomarkers lack sufficient sensitivity and specificity. tRNA-derived fragments (tRFs), an emerging class of non-coding RNAs, have garnered attention for their stability and regulatory roles in carcinogenesis.

Main body

This review adopts a comparative perspective to evaluate the distinctive roles of tRFs in GC relative to other non-coding RNAs, particularly microRNAs (miRNAs). We summarize tRF biogenesis and classification, highlighting their unique mechanistic repertoire that encompasses both AGO2-dependent gene silencing and non-canonical protein interactions. Dysregulated tRF profiles in patient samples reveal promising diagnostic candidates (e.g., tRF-23-Q99P9P9NDD, tRF-17-18VBY9M) that demonstrate superior performance to conventional markers. However, we critically examine translational barriers including functional heterogeneity, detection challenges, and the absence of registered clinical trials. We also dissect sources of contradictory findings and propose standardized frameworks for future investigation.

Conclusions

tRFs represent functionally versatile regulators with distinct advantages over miRNAs in diagnostic applications. Their clinical translation requires overcoming methodological standardization gaps and evidence thresholds through interdisciplinary efforts integrating multi-omics profiling, advanced delivery systems, and rigorous clinical validation.